Cargando…

Exploring biomarkers for prognosis and neoadjuvant chemosensitivity in rectal cancer: Multi-omics and ctDNA sequencing collaboration

INTRODUCTION: This study aimed to identified the key genes and sequencing metrics for predicting prognosis and efficacy of neoadjuvant chemotherapy (nCT) in rectal cancer (RC) based on genomic DNA sequencing in samples with different origin and multi-omics association database. METHODS: We collected...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Xiu-Feng, Zhang, Bo-Miao, Du, Fen-Qi, Guo, Jun-Nan, Wang, Dan, Li, Yi-En, Deng, Shen-Hui, Cui, Bin-Bin, Liu, Yan-Long
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780298/ https://www.ncbi.nlm.nih.gov/pubmed/36569844 http://dx.doi.org/10.3389/fimmu.2022.1013828

Ejemplares similares

Evaluation of ctDNA in the Prediction of Response to Neoadjuvant Therapy and Prognosis in Locally Advanced Rectal Cancer Patients: A Prospective Study
por: Morais, Marina, et al.
Publicado: (2023)

Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study
por: Wang, Yaqi, et al.
Publicado: (2021)

The clinical application of ctDNA to predict response to neoadjuvant chemoradiotherapy in patients with locally-advanced rectal cancer
por: Pezeshki, Parmida Sadat, et al.
Publicado: (2023)

ctDNA: An emerging neoadjuvant biomarker in resectable solid tumors
por: Abbosh, Christopher, et al.
Publicado: (2021)

Association of ctDNA detection and recurrence assessment in patients with neoadjuvant treatment
por: Zhou, Jiaxin, et al.
Publicado: (2023)

The Prognostic Importance of ctDNA in Rectal Cancer: A Critical Reappraisal
por: Dizdarevic, Edina, et al.
Publicado: (2022)

ShinyOmics: collaborative exploration of omics-data
por: Surujon, Defne, et al.
Publicado: (2020)

Role of ctDNA in Breast Cancer
por: Sant, Marta, et al.
Publicado: (2022)

The Role of ctDNA in Gastric Cancer
por: Mencel, Justin, et al.
Publicado: (2022)

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples
por: Gumà, Josep, et al.
Publicado: (2022)

ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
por: Dasari, Arvind, et al.
Publicado: (2020)

Phase II trial of delta-tocotrienol in neoadjuvant breast cancer with evaluation of treatment response using ctDNA
por: Kjær, Ina Mathilde, et al.
Publicado: (2023)

Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response
por: Zhou, Qing, et al.
Publicado: (2022)

Prognostic Value of ctDNA Mutation in Melanoma: A Meta-Analysis
por: Zheng, Yang, et al.
Publicado: (2021)

Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health
por: Williams, P. Mickey, et al.
Publicado: (2021)

Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer
por: Zhu, Chennianci, et al.
Publicado: (2020)

Liquid Biopsy, ctDNA Diagnosis through NGS
por: Lin, Chen, et al.
Publicado: (2021)

ctDNA as a biomarker of progression in oesophageal adenocarcinoma
por: Bonazzi, V.F., et al.
Publicado: (2022)

State of the Art: ctDNA in Upper Gastrointestinal Malignancies
por: Labiano, Ibone, et al.
Publicado: (2023)

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA
por: Liu, Binliang, et al.
Publicado: (2022)

Potential value of ctDNA monitoring in metastatic HR + /HER2 − breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial
por: Chiu, Joanne, et al.
Publicado: (2023)

Peripheral inflammation/immune indicators of chemosensitivity and prognosis in breast cancer patients treated with neoadjuvant chemotherapy
por: Qian, Yi, et al.
Publicado: (2018)

Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC
por: Qiu, Bin, et al.
Publicado: (2021)

Copy Number Variation of Circulating Tumor DNA (ctDNA) Detected Using NIPT in Neoadjuvant Chemotherapy-Treated Ovarian Cancer Patients
por: Sharbatoghli, Mina, et al.
Publicado: (2022)

Detection of ctDNA in the plasma of patients with papillary thyroid carcinoma
por: Li, Huiqiang, et al.
Publicado: (2019)

Current status of ctDNA in precision oncology for hepatocellular carcinoma
por: Li, Yan, et al.
Publicado: (2021)

The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma
por: Ding, Yubo, et al.
Publicado: (2022)

Current and Future Clinical Applications of ctDNA in Immuno-Oncology
por: Stadler, Julia-Christina, et al.
Publicado: (2022)

Regulatory implications of ctDNA in immuno-oncology for solid tumors
por: Vellanki, Paz J, et al.
Publicado: (2023)

CTC, ctDNA, and Exosome in Thyroid Cancers: A Review
por: Wang, Wenwen, et al.
Publicado: (2023)

The clinical utility of dynamic ctDNA monitoring in inoperable localized NSCLC patients
por: Yang, Yin, et al.
Publicado: (2022)

Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer
por: Shields, Misty Dawn, et al.
Publicado: (2022)

Exploring Circulating Tumor DNA (CtDNA) and Its Role in Early Detection of Cancer: A Systematic Review
por: Bittla, Parikshit, et al.
Publicado: (2023)

ctDNA as a prognostic biomarker in resectable CLM: Systematic review and meta-analysis
por: Wang, Da, et al.
Publicado: (2023)

Clearance of ctDNA in triple-negative and HER2-positive breast cancer patients during neoadjuvant treatment is correlated with pathologic complete response
por: Ciriaco, Nikaoly, et al.
Publicado: (2022)

Establishing the Clinical Utility of ctDNA Analysis for Diagnosis, Prognosis, and Treatment Monitoring of Retinoblastoma: The Aqueous Humor Liquid Biopsy
por: Xu, Liya, et al.
Publicado: (2021)

The Prognostic Value of ctDNA and bTMB on Immune Checkpoint Inhibitors in Human Cancer
por: Wei, Jiayan, et al.
Publicado: (2021)

Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy
por: Khatami, Fatemeh, et al.
Publicado: (2018)

The feasibility of using mutation detection in ctDNA to assess tumor dynamics
por: Yi, Xin, et al.
Publicado: (2017)

Prediction of the treatment response in ovarian cancer: a ctDNA approach
por: Sharbatoghli, Mina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_naedmn2nqm8vs7v020reiaa2av